Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

FDA approves new weight-loss pill Belviq

Arena Pharmaceutical’s weight-loss pill Belviq is for adults who are obese with at least one medical complication, such as diabetes or high cholesterol.

Associated Press

Arena Pharmaceutical’s weight-loss pill Belviq is for adults who are obese with at least one medical complication, such as diabetes or high cholesterol.

WASHINGTON — The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in more than a decade.

Despite only achieving modest weight loss in clinical studies, the drug appeared safe enough to win the FDA's endorsement, amid calls from doctors for new weight-loss treatments.

The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol.

The FDA denied approval for Arena's drug in 2010 after scientists raised concerns about tumors that developed in animals studied with the drug. The company resubmitted the drug with additional data earlier this year, and the FDA said there was little risk of tumors in humans.

"The approval of this drug, used responsibly in combination with a healthy diet and lifestyle, provides a treatment option for Americans who are obese or are overweight and have at least one weight-related comorbid condition," said FDA's drug center director, Dr. Janet Woodcock, in a statement.

Arena and its partner Eisai Inc. of Woodcliff Lake, N.J., expect to launch the drug in early 2013.

With U.S. obesity rates nearing 35 percent of the adult population, many doctors have called on the FDA to approve new weight loss treatments.

But a long line of prescription weight loss offerings have been associated with safety problems, most notably the fen-phen combination, which was linked to heart valve damage in 1997. The cocktail of phentermine and fenfluramine was a popular weight loss combination prescribed by doctors, though it was never approved by FDA.

In a rare move, the FDA explicitly stated in a press release that Belviq "does not appear to activate" a chemical pathway that was linked to the heart problems seen with fen-phen.

The FDA said the drug acts on a different chemical pathway in the brain, which is believed to reduce appetite by boosting feelings of satiety and fullness.

Obesity Society president Patrick O'Neil said he's encouraged by the drug's approval because it underscores the idea that lifestyle changes alone are not enough to treat obesity.

"This is good news because it tells us that the FDA is indeed treating obesity seriously. On the other hand, it's not the answer to the problem — or even a big part of the answer," said O'Neil, who teaches at Medical University of South Carolina and was the lead researcher on several studies of Belviq.

Even if the effects of Belviq are subtle, experts say it could be an important first step in a new line of treatments that attack the underlying causes of obesity.

"The way these things tend to work is you have some people who do extremely well and other people don't lose any weight at all," said Dr. Louis Aronne, director of the weight loss program at Weill-Cornell Medical College. "But if we had 10 medicines that were all different and worked like this, we would have a real field."

FDA approves new weight-loss pill Belviq 06/27/12 [Last modified: Wednesday, June 27, 2012 10:27pm]
Photo reprints | Article reprints

© 2017 Tampa Bay Times

    

Join the discussion: Click to view comments, add yours

Loading...
  1. Bigger ships carry Georgia ports to record cargo volumes

    Economic Development

    SAVANNAH, Ga. — Bigger ships arriving through an expanded Panama Canal pushed cargo volumes at Georgia's seaports to record levels in fiscal 2017, the Georgia Ports Authority announced Monday.

    The Port of Savannah moved a record 3.85 million container units in fiscal 2017, the state said, benefiting from the larger ships that can now pass through an expanded Panama Canal.
  2. Rays' Evan Longoria: "We have all the belief in the world in here"

    Blogs

    The weekend sweep by Texas and four-game overall losing streak has some Rays fans - based on their tweets and emails - questioning the team's ability to make the playoffs and suggesting they might as well trade away their key parts.

  3. FWC: Fish away for invasive lionfish

    Water

    Times staff

    What could be better than fishing and helping save the Gulf of Mexico?

    Add prizes.

    Lionfish, originally from the South Pacific and Indian Ocean, are an invasive species in the Gulf of Mexico. [LARA CERRI  |  Times]
  4. Gerald McCoy cares too much about what you think of him

    The Heater

    Gerald McCoy is right. We are going to miss him when he's gone.

    Bucs defensive tackle Gerald McCoy is one of 16 players to record at least five sacks in each of the past five seasons. [LOREN ELLIOTT | Times]
  5. Ronde Barber says comments about McCoy 'sensationalized'

    Blogs

    If anyone thinks Ronde Barber was throwing shade at Bucs defensive tackle Gerald McCoy, think again.

    "That anyone would assume I would say the best player on the defense isn’t a bad dude is irresponsible and sensationalizing a quote to serve their own means,'' Ronde Barber said.